Protein Biomarker Detection with Olink Proteomics


Leveraging Olink Proteomics® Proximity Extension Assay (PEA) technology, Azenta Life Sciences’ protein biomarker detection services enable detection and quantification of circulating proteins to provide an in-depth, biological understanding of disease and drug response. Unlike traditional methods, this approach enables high-throughput, simultaneous analysis of proteins with high specificity and sensitivity using minimal sample amounts. Processing is available for research use only (RUO) or can be performed in our CAP-accredited, CLIA-certified laboratory for clinical applications. 

For a multiomics approach, this proteomics service can be combined with Azenta’s genomic and transcriptomic solutions to provide a comprehensive understanding of molecular changes contributing to development, disease, and drug response in clinical trials.



How Olink® Technology Is Revolutionizing
Proteomics and Multiomics

Technologies for proteomics have lagged compared to their genomic counterparts in terms
of throughput, specificity, and cost. Learn how Olink's new assay is closing the gap


Olink Target 48 Olink Target 96 Olink Explore 3072/384 
One of the broadest human cytokine inflammation panels available, Olink Target 48 allows for analysis of proteins with the highest relevance for investigation of inflammatory processes and diseases to support clinical trials. With Olink Target 96, choose from fifteen carefully designed panels built for specific areas of human disease and key biological processes. For researchers working with mouse models, Target 96 Mouse Exploratory is also available.  Comprised of eight 384-plex human disease focused panels, Olink Explore is both flexible and scalable; you may run the entire library or focus on one or more of the 384-plex panels.

Use the Target 48 cytokine panel to elucidate:

  • In vitro therapeutic effects on the number of cytokines produced
  • Candidate biomarkers for predicting response and/or toxicity
  • The immune system mechanism of action by coupling Target 48 cytokine panel with gene expression (RNA) data 
  • Immunogenicity induced by your agent in vivo

Disease area:

  • Cardiovascular Disease II, Cardiovascular Disease III, Oncology, Oncology III, Neurology, Inflammation, Immuno-oncology

Biological process:

  • Cardiometabolic, Cell regulation, Neuro-exploratory, Immune Response, Development, Metabolism, Organ Damage

These panels are organized into four disease areas:

  • Cardiometabolic
  • Inflammation
  • Neurology
  • Oncology


  • Drug target identification & pQTLS
  • Biomarker analysis & screening
  • Exploratory endpoints in clinical trials
  • Protein response validation in clinical trials
  • Translational research studies
  • Patient stratification
  • Insights into potential disease outcome




Genomics, transcriptomics, and proteomics individually provide unique and crucial insights into the inner workings of human cells. Collectively, these –omics tools can provide detailed insights into relationships and patterns to help you accelerate and expand your search for drug targets.



Standard Deliverables

  • Absolute quantification in pg/ml (Olink Target 48 only)
  • Data in Normalized Protein Expression (NPX) format for relative quantification
  • Certificate of Analysis showing quality details – internal and external controls are included throughout the workflow to ensure data quality

Advanced Analysis

(In addition to standard deliverables)

  • Data visualization: Provides a principal component analysis and heatmap to visualize sample distribution and protein expression – results are illustrated from differential expression analysis in both table and interactive-graphic formats
  • Statistical analysis: Includes differentially expressed protein analysis – input will be absolute quantification value for Olink Target 48 or NPX value for Olink Target 96

Custom bioinformatics analysis and reports are available. Please contact us about how we can customize your analysis to answer your biological question.


Features and Benefits


  • Building

    Sample and Material Management

    Offering sample sourcing, storage, and transport of your samples
  • Building

    Fast Turnaround

    Starting at just 10 business days for expedited projects
  • Building

    Trusted Partner

    By all top 20 biopharma companies
Processing available in our CLIA/CAP laboratory for clinical applications
As little as 1 µL needed for analysis, with 40 µL & recommended for sample submission
Dual-recognition of two antibodies and DNA barcoding unique to each protein enables high specificity of protein detection – no readout of cross-reactivity
High sensitivity for protein detection, similar to ELISA or better
Increased precision (average intra %CV <10% and inter %CV <20%) across multiplex and midplex assays
Dynamic range spanning more than 10 logs, which makes it ideal for the study of the plasma proteome

Blog | How Olink® technology is revolutionizing proteomics and multiomics

Current proteomics technologies often present limitations in terms of throughput, specificity, and cost. However, new innovations, such as Olink Proteomics’ proximity extension assay (PEA) technology, are overcoming these challenges by enabling hundreds to thousands of proteins to be measured in a single sample. In this blog, discover how Azenta is leveraging PEA technology for protein biomarker discovery, its applications, and how it can complement genomics data to accelerate drug development.


Azenta is a certified service provider for Illumina and other cutting-edge NGS platforms. For information on our NGS platforms, as well as recommended configurations of your projects, please visit the NGS Platforms page. Azenta does not guarantee data output or quality for sequencing only projects. 

How To Order

Email | Phone 1-877-436-3949, Ext. 1